Urol. praxi, 2013; 14(2): 59-62

Pharmacotherapy for urgent incontinence and overactive bladder

MUDr.Miroslava Romžová
Urologická klinika FN, Hradec Králové

Overactive bladder is a syndrome that includes frequency, urgency, and urgent incontinence with or without nocturia. The treatment relies

on correct diagnosis. Lifestyle measures are the first treatment of choice. If they are not effective enough, it is necessary to initiate pharmacotherapy.

Invasive methods are used only sporadically when every other therapy has failed. Pharmacotherapy involves not only benefits,

but also numerous adverse effects. One needs to be familiar with them and approach the treatment of patients on an individual basis.

Keywords: overactive bladder, pharmacoterapy, urgent incontinence

Published: April 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Romžová M. Pharmacotherapy for urgent incontinence and overactive bladder. Urol. praxi. 2013;14(2):59-62.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Herzog AR, Fultz NH. Prevalence and incidence of urinary incontinence in community dwelling populations. J Am Geriatr Soc, 1990; 38: 273. Go to original source... Go to PubMed...
    2. Arnold J, McLeod N, Thani-Gasalam R, Rashid P. Overactive bladder syndrome - Management and treatment options. Aust Fam Physician, 2012; 41(11): 878-883. Go to PubMed...
    3. Kelleher CJ, Kreder KJ, Pleil AM, et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002; 8(Suppl 19): 616-630.
    4. Yalcin I, Hump RC. Validation of two global impression questionnaires for incontinence. AM J Obstet Gynaecol 2003; 189: 98-101. Go to original source... Go to PubMed...
    5. Matza LS, Thompson C, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn, 2005; 24: 215-225. Go to original source... Go to PubMed...
    6. Romžová M, Hurtová M, Pacovský J, Broďák M. Inkontinence moče ve stáří. Urol. Praxi, 2010; 11(3): 119-123.
    7. Poršová M, Kolombo I, Porš J, Kobzanová R, Pabišta R. Urgentní mikce a inkontinence a možnosti jejich farmakologické léčby. Urol. Praxi, 2008; 9(6): 302-306.
    8. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urol. Praxi, 2010; 11(5): 241-246.
    9. Andersson KE. Antimuscarinic mechanism and the overactive detrusor: an update. Eur. Urol., 2011; 59: 377-386. Go to original source... Go to PubMed...
    10. Topinková E. Úskalí farmakoterapie urgentní inkontinence a hyperaktivního močového měchýře. Lékařské listy, 2009; 18: 21-25.
    11. Kitisomprayoonkul W, Kovindha A. The efficacy of oxyphencyclimine hydrochloride in treatment of urinary incontinence in spinal cord injured patiens with detrusor sphincter dyssynergia. J Thai Rehabil, 2000; 10: 23-26.
    12. Klečka J, Hora M, Běhounek P, Eret V, Stránsky P. Současné možnosti léčby mikčních symptomů dolních cest močových. Urol. Praxi, 2010; 11(3): 124-130.
    13. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuskarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol, 2005; 48: 5-26. Go to original source... Go to PubMed...
    14. de la Rosette J, Alivizatos G, Madersbacher S. European Association of Urology guidlines on benign prostatic hyperplasia. http://www.uroweb.org/fileadmin/txeuguidlines/BPH.pdf.
    15. Drlík P. Nykturie - současné možnosti terapie. Urol. Praxi, 2010; 11(4): 176-179.
    16. Saks EK, Lily AA. Pharmacologic management of overactive bladder. The female patient, 2010; 11(35): 24-29.
    17. Krhut J. Současný pohled na diagnostiku inkontinence moči a léčbu. Postgraduální med., 2008; 3: 32-39.
    18. Vidlář A, Vrtal R, Študent V. Farmakologická léčba hyperaktivního močového měchýře a urgentní inkontinence. Urol. Praxi, 2007; 8(4): 158-162.
    19. Anderson KE. Current concepts in treatment of disorders of micturition. Drugs, 1988; 35: 477-494. Go to original source... Go to PubMed...
    20. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical Botulinum Toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur. Urol., 2010; 58: 919-926. Go to original source... Go to PubMed...
    21. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol, 1999; 162: 3-11. Go to original source... Go to PubMed...
    22. Kim JH, Rival DA, Shenot PJ, Green B, Kennelly M, Ericsson JR, et al. Chancellor MB Intravesical resiniferatoxin for refractory detrusor hyperreflixia: a multicenter, blinded, radomizid, placebo-cotrolled trial. J spinal Cord Med, 2003; 26: 359-363. Go to original source... Go to PubMed...
    23. de Seze M, Gallien P, Denys P, Labat JJ, Serment G, Grise P, et al. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study. Neurourol Urodyn, 2006; 25: 752-757. Go to original source... Go to PubMed...
    24. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol, 2006; 49: 644-650. Go to original source... Go to PubMed...
    25. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy, 2008; 28: 356-365. Go to original source... Go to PubMed...
    26. Kaplan SA, Walmslay K, Te AE, Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, 2005; 174: 2273-2276. Go to original source... Go to PubMed...
    27. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fistis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol, 2003; 58: 2253-2256. Go to original source... Go to PubMed...
    28. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson N, Bavendam T, Guam Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA, 2006; 296: 2319-2328. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.